Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,761
archived clinical trials in
Osteoporosis

TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
Phillip J. Mease
2
mi
from 98109
Seattle, WA
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
Phillip J. Mease
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'Osteoporosis Research Group
2
mi
from 98109
Seattle, WA
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'Osteoporosis Research Group
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'University of Wisconsin Medical Foundation
1617
mi
from 98109
Madison, WI
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'University of Wisconsin Medical Foundation
1617
mi
from 98109
Madison, WI
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
Medical College of Wisconsin
1687
mi
from 98109
Milwaukee, WI
Click here to add this to my saved trials
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/10/2015
'IDIM
mi
from 98109
Buenos Aires,
TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial With a 12-Month Interim Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/10/2015
'IDIM
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Pivotal Research
1102
mi
from 98109
Peoria, AZ
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Pivotal Research
1102
mi
from 98109
Peoria, AZ
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Loma Linda Osteoporosis Research Clinic
975
mi
from 98109
Loma Linda, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Loma Linda Osteoporosis Research Clinic
975
mi
from 98109
Loma Linda, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Steven Harris
574
mi
from 98109
Mill Valley, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Steven Harris
574
mi
from 98109
Mill Valley, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
John Wayne Cancer Institute
961
mi
from 98109
Santa Monica, CA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
John Wayne Cancer Institute
961
mi
from 98109
Santa Monica, CA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Paul Miller
1018
mi
from 98109
Lakewood, CO
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Paul Miller
1018
mi
from 98109
Lakewood, CO
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Longmont Medical Research Network
996
mi
from 98109
Longmont, CO
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Longmont Medical Research Network
996
mi
from 98109
Longmont, CO
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Radiant Research, Stuart
2660
mi
from 98109
Stuart, FL
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Radiant Research, Stuart
2660
mi
from 98109
Stuart, FL
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital
2516
mi
from 98109
Bangor, ME
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Maine Center for Osteoporosis Research and Education of St. Joseph's Hospital
2516
mi
from 98109
Bangor, ME
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
'Bethesda Health Research Center
2316
mi
from 98109
Bethesda, MD
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
'Bethesda Health Research Center
2316
mi
from 98109
Bethesda, MD
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Helen Hayes Hospital
2387
mi
from 98109
West Haverstraw, NY
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Helen Hayes Hospital
2387
mi
from 98109
West Haverstraw, NY
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Oregon Osteoporosis Center
146
mi
from 98109
Portland, OR
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Oregon Osteoporosis Center
146
mi
from 98109
Portland, OR
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Simona Scumpia
1770
mi
from 98109
Austin, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Simona Scumpia
1770
mi
from 98109
Austin, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Radiant Research Dallas
1678
mi
from 98109
Dallas, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Radiant Research Dallas
1678
mi
from 98109
Dallas, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
'Diabetes & Glandular Disease Research Associates, P.A.
1787
mi
from 98109
San Antonio, TX
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
'Diabetes & Glandular Disease Research Associates, P.A.
1787
mi
from 98109
San Antonio, TX
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Northwest Lipid Research Center
2
mi
from 98109
Seattle, WA
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Northwest Lipid Research Center
2
mi
from 98109
Seattle, WA
Click here to add this to my saved trials
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated:  11/11/2015
Heritage Medical Research Clinic
440
mi
from 98109
Calgary,
A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
A Double Blind, Placebo Controlled, Parallel-Group Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis
Status: Enrolling
Updated: 11/11/2015
Heritage Medical Research Clinic
440
mi
from 98109
Calgary,
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Osteoporosis Medical Center
mi
from 98109
Beverly Hills, CA
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Osteoporosis Medical Center
mi
from 98109
Beverly Hills, CA
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
University of Chicago
1737
mi
from 98109
Chicago, IL
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
University of Chicago
1737
mi
from 98109
Chicago, IL
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Michigan Bone and Mineral Clinic, PC
1937
mi
from 98109
Detroit, MI
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Michigan Bone and Mineral Clinic, PC
1937
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Odyssey Research Services
1009
mi
from 98109
Bismarck, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Odyssey Research Services
1009
mi
from 98109
Bismarck, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Michael J. Lillestol
1193
mi
from 98109
Fargo, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Michael J. Lillestol
1193
mi
from 98109
Fargo, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Odyssey Research Services
972
mi
from 98109
Minot, ND
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Odyssey Research Services
972
mi
from 98109
Minot, ND
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Rapid City Medical Center
949
mi
from 98109
Rapid City, SD
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Rapid City Medical Center
949
mi
from 98109
Rapid City, SD
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
Brown Clinic
1214
mi
from 98109
Watertown, SD
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
Brown Clinic
1214
mi
from 98109
Watertown, SD
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'Fletcher Allan Health Center, UHC Campus 1
2326
mi
from 98109
Burlington, VT
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'Fletcher Allan Health Center, UHC Campus 1
2326
mi
from 98109
Burlington, VT
Click here to add this to my saved trials
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated:  11/11/2015
'IDIM
mi
from 98109
Buenos Aires,
Open Label Extension
An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES)
Status: Enrolling
Updated: 11/11/2015
'IDIM
mi
from 98109
Buenos Aires,
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
University of Alabama at Birmingham
2072
mi
from 98109
Birmingham, AL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Rheumatology Associates Of North Alabama, P.C.
2038
mi
from 98109
Huntsville, AL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Rheumatology Associates Of North Alabama, P.C.
2038
mi
from 98109
Huntsville, AL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Radiant Research - Phoenix North
1112
mi
from 98109
Phoenix, AZ
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Radiant Research - Phoenix North
1112
mi
from 98109
Phoenix, AZ
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Osteoporosis Medical Center
mi
from 98109
Beverly Hills, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Osteoporosis Medical Center
mi
from 98109
Beverly Hills, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
East Bay Clinical Trial Center
667
mi
from 98109
Concord, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
East Bay Clinical Trial Center
667
mi
from 98109
Concord, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Loma Linda Osteoporosis Research Center
974
mi
from 98109
Loma Linda, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Loma Linda Osteoporosis Research Center
974
mi
from 98109
Loma Linda, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Foundation for Osteoporosis Research
678
mi
from 98109
Oakland, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Foundation for Osteoporosis Research
678
mi
from 98109
Oakland, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Desert Medical Advances
1010
mi
from 98109
Palm Desert, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Desert Medical Advances
1010
mi
from 98109
Palm Desert, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
VA Palo Alto Health Care System
707
mi
from 98109
Palo Alto, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
VA Palo Alto Health Care System
707
mi
from 98109
Palo Alto, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Boling Clinical Trials
967
mi
from 98109
Rancho Cucamonga, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Boling Clinical Trials
967
mi
from 98109
Rancho Cucamonga, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'S.D. Arthritis & Osteoporosis Medical Clinic
1065
mi
from 98109
san Diego, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'S.D. Arthritis & Osteoporosis Medical Clinic
1065
mi
from 98109
san Diego, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Radiant Research - San Diego
1065
mi
from 98109
San Diego, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Radiant Research - San Diego
1065
mi
from 98109
San Diego, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
San Francisco General Hospital
683
mi
from 98109
San Francisco, CA
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
San Francisco General Hospital
683
mi
from 98109
San Francisco, CA
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
Longmont Medical Research Network
996
mi
from 98109
Longmont, CO
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
Longmont Medical Research Network
996
mi
from 98109
Longmont, CO
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Northeast Clinical Research, LLC
2431
mi
from 98109
Hamden, CT
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Northeast Clinical Research, LLC
2431
mi
from 98109
Hamden, CT
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
RASF Clinical Research Center
2708
mi
from 98109
Boca Raton, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
RASF Clinical Research Center
2708
mi
from 98109
Boca Raton, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
The Center for Diabetes and Endocrine Care
2719
mi
from 98109
Hollywood, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
The Center for Diabetes and Endocrine Care
2719
mi
from 98109
Hollywood, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Florida Wellcare Alliance
2490
mi
from 98109
Inverness, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Florida Wellcare Alliance
2490
mi
from 98109
Inverness, FL
Click here to add this to my saved trials
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated:  11/11/2015
'Renstar Medical Group
2483
mi
from 98109
Ocala, FL
Open Label Extension Study of PREOS
An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women With Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001 (TOP Study)
Status: Enrolling
Updated: 11/11/2015
'Renstar Medical Group
2483
mi
from 98109
Ocala, FL
Click here to add this to my saved trials